Yuhao Zeng
A5035563690- Renal cell carcinoma treatment
- Epigenetics and DNA Methylation
- Phagocytosis and Immune Regulation
- Cancer, Hypoxia, and Metabolism
- Biotin and Related Studies
- Renal and related cancers
- Enzyme function and inhibition
- Cancer Treatment and Pharmacology
- Prostate Cancer Treatment and Research
- Ferroptosis and cancer prognosis
- Cancer Immunotherapy and Biomarkers
- Metabolism, Diabetes, and Cancer
- PI3K/AKT/mTOR signaling in cancer
- Pancreatic and Hepatic Oncology Research
- Diet and metabolism studies
- Prostate Cancer Diagnosis and Treatment
- Click Chemistry and Applications
- Multiple and Secondary Primary Cancers
- Endoplasmic Reticulum Stress and Disease
- Advanced Radiotherapy Techniques
- Urinary and Genital Oncology Studies
- Pancreatic function and diabetes
- Cancer, Lipids, and Metabolism
- Urologic and reproductive health conditions
- Regulation of Appetite and Obesity
Sichuan University
2022-2024
Tokyo Metropolitan University
2024
Guangzhou University of Chinese Medicine
2024
West China Hospital of Sichuan University
2022-2023
Creative Commons
2023
Multidisciplinary team (MDT) discussion is a widely used model to manage patients diagnosed with cancer. However, there has been no direct evidence prove its effect on the prognosis of metastatic renal cell carcinoma (mRCC) patients, so this study explored impact MDT mRCC patient survival.The clinical data 269 were retrospectively collected from 2012 2021. The cases grouped into and non-MDT groups, then subgroup analysis was performed according different histology types, as well exploring...
Abstract Purpose: Fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) is a rare and lethal subtype of kidney cancer. However, the optimal treatments molecular correlates benefits for FH-deficient RCC are currently lacking. Experimental Design: A total 91 patients with from 15 medical centers between 2009 2022 were enrolled in this study. Genomic bulk RNA-sequencing (RNA-seq) performed on 88 45 untreated RCCs, respectively. Single-cell RNA-seq was to identify biomarkers...
This study aims to investigate whether baicalin induces ferroptosis in HepG2 cells and decipher the underlying mechanisms based on network pharmacology cell experiments. were cultured vitro viability was detected by counting kit-8(CCK-8). The transcriptome data of hepatocellular carcinoma obtained from Cancer Genome Atlas(TCGA), gene FerrDb V2. DEG2 package used screen differentially expressed genes(DEGs), common genes between DEGs selected as target that mediate regulate progression....
Clear cell renal carcinoma (ccRCC) is the most common type of kidney cancer. The maximum number deaths associated with cancer can be attributed to ccRCC. Disruption cellular proteostasis results in endoplasmic reticulum (ER) stress, which various aspects It noteworthy that role ER stress progression ccRCC remains unclear. We classified 526 samples identified from TCGA database into C1 and C2 subtypes by consensus clustering 295 stress-related genes. belonging subtype were their advanced...
Clear cell renal carcinoma (ccRCC) is the most common and highly heterogeneous subtype of carcinoma. Dysregulated basal adhesion molecule (BCAM) gene associated with poor prognosis in various cancers. However, dysregulated functions related multi-omics features BCAM ccRCC stay unclear.BCAM expression was aberrantly downregulated correlated adverse pathological parameters prognosis. Low mRNA remarkably its CpG methylation levels BAP1 mutation status. Patients lower-expressed concomitant had a...
Mucinous adenocarcinoma of the kidney is rarely reported in literature. We present a previously unreported mucinous arising from renal parenchyma. A 55-year-old male patient with no complaints showed large cystic hypodense lesion upper left on contrast-enhanced computed tomography (CT) scan. cyst was initially considered, and partial nephrectomy (PN) performed. During operation, amount jelly-like mucus bean-curd-like necrotic tissue found focus. The pathological diagnosis adenocarcinoma,...
<div>AbstractPurpose:<p>Fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) is a rare and lethal subtype of kidney cancer. However, the optimal treatments molecular correlates benefits for FH-deficient RCC are currently lacking.</p>Experimental Design:<p>A total 91 patients with from 15 medical centers between 2009 2022 were enrolled in this study. Genomic bulk RNA-sequencing (RNA-seq) performed on 88 45 untreated RCCs, respectively. Single-cell...
<p>Supplementary Figure 2. Treatment details and survival outcomes of patients with metastatic FH-deficient RCC. (A) Swimmer plot showing the treatment response duration each patient receiving first-line systemic treatments; (B) Progression-free for (C) Overall (OS) treatments.</p>
<p>Supplementary Figure 6. Validation of the FH-deficient RCC immune signature. (A) UMAP plot showing expression selected genes; (B) Correlations between six genes in signature and treatment response, significance differential (q value) was determined by two-sided Wilcoxon rank-sum test with Bonferroni FDR correction; (C) several related hallmark pathways, correction. *, q<0.05; **, q<0.01; ***, q<0.001; ****, q<0.0001.</p>
<p>Supplementary Figure 3. Forest plot showing the prognostic value of clinicopathologic and molecular features in patients treated with first-line ICI+TKI combination therapy. HR<1 indicates better survival comparator group, while HR>1 control group. TMB, tumor mutation burden; MUT, mutation; WT, wild type; TPS, proportion score; CCP, cell cycle progression; Sig., signature.</p>
<p>Supplementary Figure 6. Validation of the FH-deficient RCC immune signature. (A) UMAP plot showing expression selected genes; (B) Correlations between six genes in signature and treatment response, significance differential (q value) was determined by two-sided Wilcoxon rank-sum test with Bonferroni FDR correction; (C) several related hallmark pathways, correction. *, q<0.05; **, q<0.01; ***, q<0.001; ****, q<0.0001.</p>
<p>Supplementary Figure 5. Cell clusters and their distribution in a validation cohort by Dong et al.. (A) UMAP plot showing the sample of T cells; (B) all cells collected from four samples; (C) Dot marker gene expression for clusters; (D) Bar plots tissue (E) Tissue prevalence cell estimated Ro/e score.</p>